(Q36620597)

15 August 2017

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee (English)

1 reference

15 August 2017

1 reference

1 reference

Twelves CJ

1

1 reference

15 August 2017

Gardner C

2

1 reference

15 August 2017

Flavin A

3

1 reference

15 August 2017

Sludden J

4

1 reference

15 August 2017

Dennis I

5

1 reference

15 August 2017

de Bono J

6

1 reference

15 August 2017

Beale P

7

1 reference

15 August 2017

Vasey P

8

1 reference

15 August 2017

Hutchison C

9

1 reference

15 August 2017

Macham MA

10

1 reference

15 August 2017

Rodriguez A

11

1 reference

15 August 2017

Judson I

12

1 reference

15 August 2017

Bleehen NM

13

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

80

1 reference

15 August 2017

11

1 reference

15 August 2017

1786-1791

1 reference

Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Microculture-Based Chemosensitivity Testing: A Feasibility Study Comparing Freshly Explanted Human Melanoma Cells With Human Melanoma Cell Lines

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Effects of CPT-11 in combination with other anti-cancer agents in culture

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363132

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

20 September 2018

1 reference

12 December 2020

Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients

1 reference

12 December 2020

Phase I study of CPT-11 and etoposide in patients with refractory solid tumors

1 reference

12 December 2020

Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6690598

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

10468297

1 reference